Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-29T17:21:50.315Z Has data issue: false hasContentIssue false

6 - Conditioning regimens

Published online by Cambridge University Press:  05 November 2013

Joseph H. Antin
Affiliation:
Dana-Farber Cancer Institute, Boston
Deborah Yolin Raley
Affiliation:
Dana-Farber Cancer Institute, Boston
Get access

Summary

Conditioning regimens aredesigned to destroy tumor cells resistant to conventional doses ofchemotherapy without causing fatal nonhematologic organ toxicity. Inpatients undergoing allogeneic stem cell transplantation, conditioningregimens must be sufficiently immunosuppressive to prevent the recipientfrom mounting an immune response capable of rejecting the graft. Graftrejection is uncommon, but this complication is associated with a direoutcome and the risk increases with the degree of mismatch.

There are few randomizedtrials comparing different ablative regimens; in general, increasedintensity of the conditioning regimen may decrease relapse rates, butusually (though not always) at the expense of increased nonrelapse morbidityand mortality. The following represent some of the more common regimens usedtoday, although different combinations and doses may be used at differentcenters. It is essential to check the specific protocol that applies to thepatient for drugs, doses, frequency, and other specifics of treatments.Biologic agents such as Campath® or antithymocyte globulin (ATG)may be added to enhance immunosuppression. See Appendix for ideal bodyweight (IBW) and adjusted ideal body weight (AIBW) for obese patients. Table6.1 summarizes currently used regimens.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Armand, P, Antin, JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant 2007; 13: 505–16.CrossRefGoogle ScholarPubMed
Soiffer, RJ, Lerademacher, J, Ho, V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963–70.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×